Literature DB >> 21871919

Infectious prion protein alters manganese transport and neurotoxicity in a cell culture model of prion disease.

Dustin P Martin1, Vellareddy Anantharam, Huajun Jin, Travis Witte, Robert Houk, Arthi Kanthasamy, Anumantha G Kanthasamy.   

Abstract

Protein misfolding and aggregation are considered key features of many neurodegenerative diseases, but biochemical mechanisms underlying protein misfolding and the propagation of protein aggregates are not well understood. Prion disease is a classical neurodegenerative disorder resulting from the misfolding of endogenously expressed normal cellular prion protein (PrP(C)). Although the exact function of PrP(C) has not been fully elucidated, studies have suggested that it can function as a metal binding protein. Interestingly, increased brain manganese (Mn) levels have been reported in various prion diseases indicating divalent metals also may play a role in the disease process. Recently, we reported that PrP(C) protects against Mn-induced cytotoxicity in a neural cell culture model. To further understand the role of Mn in prion diseases, we examined Mn neurotoxicity in an infectious cell culture model of prion disease. Our results show CAD5 scrapie-infected cells were more resistant to Mn neurotoxicity as compared to uninfected cells (EC(50)=428.8 μM for CAD5 infected cells vs. 211.6 μM for uninfected cells). Additionally, treatment with 300 μM Mn in persistently infected CAD5 cells showed a reduction in mitochondrial impairment, caspase-3 activation, and DNA fragmentation when compared to uninfected cells. Scrapie-infected cells also showed significantly reduced Mn uptake as measured by inductively coupled plasma-mass spectrometry (ICP-MS), and altered expression of metal transporting proteins DMT1 and transferrin. Together, our data indicate that conversion of PrP to the pathogenic isoform enhances its ability to regulate Mn homeostasis, and suggest that understanding the interaction of metals with disease-specific proteins may provide further insight to protein aggregation in neurodegenerative diseases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871919      PMCID: PMC3205977          DOI: 10.1016/j.neuro.2011.07.008

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  98 in total

Review 1.  Twenty years of metallo-neurobiology: where to now?

Authors:  Ashley I Bush; Cyril C Curtain
Journal:  Eur Biophys J       Date:  2007-11-10       Impact factor: 1.733

2.  Raman optical activity and circular dichroism reveal dramatic differences in the influence of divalent copper and manganese ions on prion protein folding.

Authors:  Fujiang Zhu; Paul Davies; Andrew R Thompsett; Sharon M Kelly; George E Tranter; Lutz Hecht; Neil W Isaacs; David R Brown; Laurence D Barron
Journal:  Biochemistry       Date:  2008-01-19       Impact factor: 3.162

Review 3.  The environment, epigenetics and amyloidogenesis.

Authors:  Jinfang Wu; Md Riyaz Basha; Nasser H Zawia
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

4.  Normal cellular prion protein protects against manganese-induced oxidative stress and apoptotic cell death.

Authors:  Christopher J Choi; Vellareddy Anantharam; Nathan J Saetveit; Robert S Houk; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Toxicol Sci       Date:  2007-05-04       Impact factor: 4.849

5.  Prion strain discrimination in cell culture: the cell panel assay.

Authors:  Sukhvir P Mahal; Christopher A Baker; Cheryl A Demczyk; Emery W Smith; Christian Julius; Charles Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

6.  Elevated manganese levels in blood and CNS in human prion disease.

Authors:  Shirley Hesketh; Judyth Sassoon; Robert Knight; David R Brown
Journal:  Mol Cell Neurosci       Date:  2007-12-15       Impact factor: 4.314

7.  Manganese binding to the prion protein.

Authors:  Marcus W Brazier; Paul Davies; Esmie Player; Frank Marken; John H Viles; David R Brown
Journal:  J Biol Chem       Date:  2008-03-10       Impact factor: 5.157

8.  Modulation of proteinase K-resistant prion protein in cells and infectious brain homogenate by redox iron: implications for prion replication and disease pathogenesis.

Authors:  Subhabrata Basu; Maradumane L Mohan; Xiu Luo; Bishwajit Kundu; Qingzhong Kong; Neena Singh
Journal:  Mol Biol Cell       Date:  2007-06-13       Impact factor: 4.138

9.  Opposing roles of prion protein in oxidative stress- and ER stress-induced apoptotic signaling.

Authors:  Vellareddy Anantharam; Arthi Kanthasamy; Christopher J Choi; Dustin P Martin; Calivarathan Latchoumycandane; Jüergen A Richt; Anumantha G Kanthasamy
Journal:  Free Radic Biol Med       Date:  2008-09-13       Impact factor: 7.376

10.  Inherited prion disease with 5-OPRI: phenotype modification by repeat length and codon 129.

Authors:  S Mead; T E F Webb; T A Campbell; J Beck; J M Linehan; S Rutherfoord; S Joiner; J D F Wadsworth; J Heckmann; S Wroe; L Doey; A King; J Collinge
Journal:  Neurology       Date:  2007-08-21       Impact factor: 9.910

View more
  10 in total

1.  Effect of divalent metals on the neuronal proteasomal system, prion protein ubiquitination and aggregation.

Authors:  A G Kanthasamy; C Choi; H Jin; D S Harischandra; V Anantharam; A Kanthasamy
Journal:  Toxicol Lett       Date:  2012-09-17       Impact factor: 4.372

2.  p73 gene in dopaminergic neurons is highly susceptible to manganese neurotoxicity.

Authors:  Dong-Suk Kim; Huajun Jin; Vellareddy Anantharam; Richard Gordon; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Neurotoxicology       Date:  2016-04-20       Impact factor: 4.294

Review 3.  Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases.

Authors:  Wei Zheng; Andrew D Monnot
Journal:  Pharmacol Ther       Date:  2011-11-13       Impact factor: 12.310

4.  Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains.

Authors:  Ajay Singh; Liuting Qing; Qingzhong Kong; Neena Singh
Journal:  Neurobiol Dis       Date:  2011-12-11       Impact factor: 5.996

5.  Prion protein functions as a ferrireductase partner for ZIP14 and DMT1.

Authors:  Ajai K Tripathi; Swati Haldar; Juan Qian; Amber Beserra; Srinivas Suda; Ajay Singh; Ulrich Hopfer; Shu G Chen; Michael D Garrick; Jerrold R Turner; Mitchell D Knutson; Neena Singh
Journal:  Free Radic Biol Med       Date:  2015-04-08       Impact factor: 7.376

6.  α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.

Authors:  Dilshan S Harischandra; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Toxicol Sci       Date:  2014-11-21       Impact factor: 4.849

7.  Role of proteolytic activation of protein kinase Cδ in the pathogenesis of prion disease.

Authors:  Dilshan S Harischandra; Naveen Kondru; Dustin P Martin; Arthi Kanthasamy; Huajun Jin; Vellareddy Anantharam; Anumantha G Kanthasamy
Journal:  Prion       Date:  2014 Jan-Feb       Impact factor: 3.931

Review 8.  Antioxidant and Metal Chelation-Based Therapies in the Treatment of Prion Disease.

Authors:  Marcus W Brazier; Anthony G Wedd; Steven J Collins
Journal:  Antioxidants (Basel)       Date:  2014-04-21

9.  Integrated Organotypic Slice Cultures and RT-QuIC (OSCAR) Assay: Implications for Translational Discovery in Protein Misfolding Diseases.

Authors:  Naveen Kondru; Sireesha Manne; Justin Greenlee; Heather West Greenlee; Vellareddy Anantharam; Patrick Halbur; Arthi Kanthasamy; Anumantha Kanthasamy
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

10.  Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress.

Authors:  Arunkumar Asaithambi; Muhammet Ay; Huajun Jin; Anamitra Gosh; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.